Medicus Pharma LTD 10-Q quarterly reports

Medicus Pharma Ltd. filed its Q2 2026 Form 10-Q, detailing increased operating expenses, substantial net losses, and a warning about its ability to continue as a going concern, though clinical trial progress was noted.

Medicus Pharma Ltd. reported a significant increase in net loss for Q1 2026, driven by higher operating expenses, while advancing its clinical pipeline and completing strategic acquisitions.

Medicus Pharma Ltd. reported a significantly increased net loss for Q3 2025, driven by higher R&D expenses including the Antev acquisition, while raising substantial capital through equity and debt.

Medicus Pharma Ltd. reported a significant increase in net loss for Q2 2025, driven by higher R&D and administrative costs, while actively pursuing strategic acquisitions and multiple capital raises.

Medicus Pharma reports a net loss for Q1 2025 while advancing its clinical trial for SkinJect and securing additional financing through a Regulation A offering and a Standby Equity Purchase Agreement.